STOCKHOLDERS’ EQUITY (Tables)
|
3 Months Ended |
Jun. 30, 2026 |
|---|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| SCHEDULE OF RESTRICTED STOCK AWARDS |
A
summary of the Company’s restricted stock unit awards for the three months ended June 30, 2026 is as follows:
SCHEDULE OF RESTRICTED STOCK AWARDS
| | |
Number Of
Shares | | |
Weighted
Average Grant
Date Fair Value | |
| | |
| | |
| |
| Unvested as of March 31, 2026 | |
| 475 | | |
$ | 2,588.20 | |
| Granted | |
| - | | |
| - | |
| Vested | |
| - | | |
| - | |
| Forfeited | |
| - | | |
| - | |
| Unvested as of June 30, 2026 | |
| 475 | | |
$ | 2,588.20 | |
|
| SCHEDULE OF FAIR VALUE OF OPTION |
The
following was utilized to calculate the fair value of options on the date of grant:
SCHEDULE
OF FAIR VALUE OF OPTION
| | |
June 30, 2026 | | |
June 30, 2025 | |
| Risk-free interest rate | |
| 4.26 | % | |
| 4.0 – 4.2 | % |
| Expected volatility (Beyond Air) | |
| 103.9 | % | |
| 91.6 – 95.7 | % |
| Expected volatility (Beyond Cancer) | |
| N/A | % | |
| N/A | % |
| Expected volatility (NeuroNos) | |
| N/A | % | |
| 95 | % |
| Dividend yield | |
| 0 | % | |
| 0 | % |
| Expected terms (in years) | |
| 6.25 | | |
| 6.25 | |
|
| SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE |
The
following summarizes the components of stock-based compensation expense which included stock options and restricted stock units for the
three months ended June 30, 2026 and June 30, 2025:
SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE
| | |
2026 | | |
2025 | |
| | |
Three Months Ended | |
| (in thousands) | |
June 30, | |
| | |
2026 | | |
2025 | |
| | |
| | |
| |
| Research and development | |
$ | 110 | | |
$ | 300 | |
| General and administrative | |
| 926 | | |
| 1,277 | |
| Total stock-based compensation expense | |
$ | 1,036 | | |
$ | 1,577 | |
|
| SUMMARY OF OUTSTANDING WARRANTS |
A
summary of the Company’s outstanding warrants as of June 30, 2026 is as follows:
SUMMARY
OF OUTSTANDING WARRANTS
| Warrant Holders | |
Number
of
Warrants | | |
Exercise
Price | | |
Intrinsic
Value
(in
thousands) | | |
Date
of
Expiration | |
| | |
| | |
| | |
| | |
| |
| NitricGen agreement | |
| 200 | | |
$ | 2,760.00 | | |
$ | - | | |
| January 2028 | |
| Avenue agreement | |
| 585 | | |
$ | 151.72 | | |
| - | | |
| June 2028 | |
| March 2024 raise | |
| 24,108 | | |
$ | 900.00 | | |
| - | | |
| March 2027 | |
| Avenue extension agreement | |
| 250 | | |
$ | 512.00 | | |
| - | | |
| June 2029 | |
| September 2024 equity offering | |
| 27,764 | | |
$ | 151.72 | | |
| - | | |
| September 2029 | |
| September 2024 debt instrument | |
| 63,542 | | |
$ | 39.00 | | |
| - | | |
| September 2029 / November 2030 | |
| September 2025 inducement | |
| 35,982 | | |
$ | 44.20 | | |
| - | | |
| September 2030 | |
| January 2026 equity offering | |
| 196,542 | | |
$ | 22.94 | | |
| - | | |
| January 2031 | |
| Subtotal | |
| 348,973 | | |
$ | 101.03 | | |
$ | - | | |
| | |
| | |
| | | |
| | | |
| | | |
| | |
| Pre-funded warrants (Sep-2024 offering) | |
| 11,002 | | |
$ | 0.040 | | |
$ | 98 | | |
| September 2029 | |
| Pre-funded warrants (Jan-2026 offering) | |
| 12,131 | | |
$ | 0.002 | | |
$ | 108 | | |
| January 2031 | |
| Total | |
| 372,106 | | |
$ | 94.75 | | |
$ | 206 | | |
| | |
|
| 2013 Beyond Air Equity Incentive Plan [Member] |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| SCHEDULE OF OPTION ACTIVITY FOR NEURONOS |
A
summary of the change in stock options for the three months ended June 30, 2026 is as follows:
SCHEDULE OF OPTION ACTIVITY
| | |
Number of
Options | | |
Weighted
Average
Exercise
Price of
Options | | |
Weighted
Average
Remaining
Contractual
Life of
Options | | |
Aggregate
Intrinsic
Value
(in thousands) | |
| | |
| | |
| | |
| | |
| |
| Options outstanding as of March 31, 2026 | |
| 37,966 | | |
$ | 36.42 | | |
| 7.2 | | |
$ | - | |
| Granted | |
| 575 | | |
| 8.92 | | |
| - | | |
| - | |
| Exercised | |
| - | | |
| - | | |
| - | | |
| - | |
| Forfeited | |
| (364 | ) | |
| 38.30 | | |
| - | | |
| - | |
| Outstanding as of June 30, 2026 | |
| 38,177 | | |
$ | 35.99 | | |
| 7.0 | | |
$ | - | |
| Exercisable as of June 30, 2026 | |
| 24,807 | | |
$ | 39.00 | | |
| 6.0 | | |
$ | - | |
|
| 2021 Beyond Cancer Ltd Equity Incentive Plan [Member] |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| SCHEDULE OF OPTION ACTIVITY FOR NEURONOS |
SCHEDULE
OF OPTION ACTIVITY FOR BEYOND CANCER
| | |
Number
of
Options | | |
Weighted
Average
Exercise
Price
of
Options | | |
Weighted
Average
Remaining
Contractual
Life
of
Options | | |
Aggregate
Intrinsic
Value
(thousands) | |
| | |
| | |
| | |
| | |
| |
| Options outstanding as of March 31, 2026 | |
| 2,254,500 | | |
$ | 5.50 | | |
| 6.2 | | |
$ | - | |
| Granted | |
| - | | |
| - | | |
| - | | |
| - | |
| Exercised | |
| - | | |
| - | | |
| - | | |
| - | |
| Forfeited | |
| (25,750 | ) | |
| 5.50 | | |
| - | | |
| - | |
| Outstanding as of June 30, 2026 | |
| 2,228,750 | | |
$ | 5.50 | | |
| 5.9 | | |
$ | - | |
| Exercisable as of June 30, 2026 | |
| 2,087,500 | | |
$ | 5.50 | | |
| 5.9 | | |
$ | - | |
|
| 2023 Neuro Nos Ltd Equity Incentive Plan [Member] |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
| SCHEDULE OF OPTION ACTIVITY FOR NEURONOS |
A
summary of the change in stock options for NeuroNos for the three months ended June 30, 2026 is as follows:
SCHEDULE
OF OPTION ACTIVITY FOR NEURONOS
| | |
Number
of
Options | | |
Weighted
Average
Exercise
Price
of
Options | | |
Weighted
Average
Remaining
Contractual
Life
of
Options | | |
Aggregate
Intrinsic
Value
(thousands) | |
| | |
| | |
| | |
| | |
| |
| Options outstanding as of March 31, 2026 | |
| 1,259,329 | | |
$ | 0.24 | | |
| 8.1 | | |
$ | 3,477 | |
| Granted | |
| - | | |
| - | | |
| - | | |
| - | |
| Exercised | |
| - | | |
| - | | |
| - | | |
| - | |
| Forfeited | |
| (478 | ) | |
| 3.00 | | |
| - | | |
| - | |
| Outstanding as of June 30, 2026 | |
| 1,258,851 | | |
$ | 0.24 | | |
| 7.8 | | |
$ | 3,477 | |
| Exercisable as of June 30, 2026 | |
| 851,363 | | |
$ | 0.18 | | |
| 7.8 | | |
$ | 2,404 | |
|